Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Secondary Resistance”

1,717 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 1,717 results

Testing effectiveness (Phase 2)Study completedNCT00887458
What this trial is testing

A Two-dose Level Clinical Trial of Itraconazole in Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While on Hormonal Therapy

Who this might be right for
Prostate Cancer
Johns Hopkins University 46
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07778940
What this trial is testing

Thiotepa Administration Via Ommaya Reservoir for Leptomeningeal Metastases in Non-Small Cell Lung Cancer Resistant to EGFR-TKI.

Who this might be right for
Leptomeningeal Metastasis
Tianjin Medical University Cancer Institute and Hospital 50
Not applicableStudy completedNCT02353715
What this trial is testing

Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing

Who this might be right for
Prostate Cancer
Duke University 38
Not applicableActive Not RecruitingNCT03364621
What this trial is testing

Comprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Response & Resistance to Cancer Therapy

Who this might be right for
Colorectal CancerColorectal Cancer MetastaticHepatic Metastases
University Health Network, Toronto 17
Testing effectiveness (Phase 2)Study completedNCT01519414
What this trial is testing

Tivantinib in Treating Patients With Metastatic Prostate Cancer

Who this might be right for
Hormone-Resistant Prostate CancerProstate AdenocarcinomaRecurrent Prostate Carcinoma+1 more
National Cancer Institute (NCI) 78
Large-scale testing (Phase 3)Study completedNCT00917384
What this trial is testing

Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma

Who this might be right for
Gastric CancerAdenocarcinoma
Eli Lilly and Company 355
Testing effectiveness (Phase 2)Looking for participantsNCT06567015
What this trial is testing

Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Pierre Fabre Medicament 171
Testing effectiveness (Phase 2)Study completedNCT03179904
What this trial is testing

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Who this might be right for
Advanced Breast CarcinomaHER2-Positive Breast CarcinomaAnatomic Stage III Breast Cancer AJCC v8+2 more
Mayo Clinic 17
Early research (Phase 1)Ended earlyNCT04249947
What this trial is testing

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Who this might be right for
Prostatic Neoplasms, Castration-ResistantNeoplasms by Histologic TypeNeoplasms, Prostate+14 more
Poseida Therapeutics, Inc. 40
Post-approval studies (Phase 4)Study completedNCT02405858
What this trial is testing

Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer
Janssen Pharmaceutical K.K. 51
Testing effectiveness (Phase 2)Study completedNCT02344017
What this trial is testing

Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Orion Corporation, Orion Pharma 23
Testing effectiveness (Phase 2)Active Not RecruitingNCT04127110
What this trial is testing

Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients

Who this might be right for
Non Small Cell Lung Cancer
European Organisation for Research and Treatment of Cancer - EORTC 68
Early research (Phase 1)Study completedNCT02202447
What this trial is testing

Phase 1 of EC1169 In Patients With Recurrent MCRPC

Who this might be right for
Prostate Cancer
Endocyte 40
Testing effectiveness (Phase 2)Ended earlyNCT01602315
What this trial is testing

A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Who this might be right for
Recurrent Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell Carcinoma
Novartis Pharmaceuticals 179
Testing effectiveness (Phase 2)UnknownNCT02525068
What this trial is testing

Enzalutamide in Combination With AZD5363 in Patients With mCRPC

Who this might be right for
Adenocarcinoma of the Prostate
Institute of Cancer Research, United Kingdom 136
Not applicableStudy completedNCT06461689
What this trial is testing

Comparison of Changes in Tumor Burden in 68Ga-PSMA-11 PET/CT and 177Lu-PSMA SPECT/CT in Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Prostate Cancer Metastatic
Central Hospital, Nancy, France 80
Not applicableActive Not RecruitingNCT04567368
What this trial is testing

TB-CAPT MTB/XDR Study

Who this might be right for
TuberculosisResistance BacterialDiagnoses Disease
Foundation for Innovative New Diagnostics, Switzerland 753
Large-scale testing (Phase 3)Looking for participantsNCT07213674
What this trial is testing

Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Amgen 750
Early research (Phase 1)Active Not RecruitingNCT04898634
What this trial is testing

JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

Who this might be right for
Prostatic Neoplasms
Janssen Research & Development, LLC 216
Early research (Phase 1)Ended earlyNCT02478125
What this trial is testing

Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 3
Next Page